Tizona Therapeutics, Inc., a privately held, clinical stage company developing first-in-class cancer immunotherapies, announced that its Investigational New Drug application for TTX-080, a novel antibody targeting HLA-G, has been cleared by the U.S. Food and Drug Administration.
June 25, 2020
· 1 min read